Please visit the Southern Regional AHEC website to register and see a full listing of all their upcoming courses.
Date: Feb 16, 2018 10:00 AM - 04:00 PM
- Pharmacy Technicians
Participants have 60 days from the start of their program to claim CE credit and verify it has been upload to CPE Monitor. If your program requires the completion of a post test/eval/survey those items MUST be done before that 60 day window closes to receive credit for that program. Statements of credit can be viewed and printed from CPE Monitor. Statements of credit will no longer be printed and mailed to the participant. **No partial individual session credit will be given**
REGISTRATION NOTE: During the registration process, if a fee is required, please enter the zip code associated with your credit card's BILLING ADDRESS. For security purposes payments are processed through a separate system, so when prompted, please click “ok” to be taken to that site and complete your registration. Upon successful registration of this program you will receive an email confirmation/receipt and will be returned to this program page. When you are retuned to this page you will see a note at the top of the page reading “You are registered for this program.”
If you are not automatically returned to this page or see only a blank white screen your transaction was not successful, and you will need to try again.
If paying by check please mail to the address below:
301 Pharmacy Lane, CB# 7574 Beard Hall
Chapel Hill, NC 27599
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Southern Regional AHEC
Please join us for "A Day For Updates" that will provide an overview on new oral chemotherapy medications, review of the CAR-T cell therapy, epidemiology of HIV and new treatment options, along with the history of integrative medicine and types of modalities of integrative medicine.
- Identify new oral chemotherapy medications and summarize the data leading to FDA approval of these agents
- Explain the mechanism of action of these novel antineoplastic agents and discuss common toxicities and monitoring recommendations
- Describe the mechanism of action of checkpoint inhibitor therapies and list the currently approved agents
- Recognize common and serious immune-related adverse events and describe management options
- Review Chimeric Antigen Receptor-T (CAR-T) Cell Therapy and its role within current practice including mechanism and toxicities
Time: 10:00 AM - 04:00 PM